Literature DB >> 23881910

Interactions between alcohol and the HIV entry inhibitor Maraviroc.

Valerie A Gruber1, Petrie M Rainey, Paula J Lum, George W Beatty, Francesca T Aweeka, Elinore F McCance-Katz.   

Abstract

BACKGROUND: Alcohol use is common among people with HIV, and beliefs about alcohol interactions with medications predict decreased medication adherence, risking drug-resistant mutations. Maraviroc is an HIV entry inhibitor approved for treatment of both drug-sensitive and drug-resistant HIV strains. The present study evaluated the effects of alcohol on maraviroc pharmacokinetics and the effects of maraviroc on alcohol pharmacokinetics.
METHODS: Ten healthy adults completed alcohol (1 g/kg) and placebo alcohol pharmacokinetics sessions before and after 7 days of maraviroc administration.
RESULTS: Alcohol concentrations increased 12% following maraviroc. Maraviroc pharmacokinetics were unaffected by alcohol.
CONCLUSIONS: Maraviroc treatment should not be interrupted if alcohol is consumed.

Entities:  

Keywords:  HIV/AIDS; alcohol; drug interactions; maraviroc

Mesh：

Substances：

Year:  2013        PMID： 23881910      PMCID： PMC4100473          DOI： 10.1177/2325957413495567

Source DB:  PubMed          Journal:  J Int Assoc Provid AIDS Care        ISSN： 2325-9574


  10 in total

Review 1.  Alcohol and aldehyde dehydrogenase.

Authors:  T Ehrig; W F Bosron; T K Li
Journal:  Alcohol Alcohol       Date:  1990       Impact factor: 2.826

2.  Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

Authors:  Elinore F McCance-Katz; David E Moody; Gene D Morse; Gerald Friedland; Patricia Pade; Jennifer Baker; Anika Alvanzo; Patrick Smith; Abayomi Ogundele; Peter Jatlow; Petrie M Rainey
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

Review 3.  The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role.

Authors:  Charles S Lieber
Journal:  Drug Metab Rev       Date:  2004-10       Impact factor: 4.518

4.  Untreated HIV infection is associated with higher blood alcohol levels.

Authors:  Elinore F McCance-Katz; Paula J Lum; George Beatty; Valerie A Gruber; Marion Peters; Petrie M Rainey
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

5.  Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection.

Authors:  Geetanjali Chander; Bryan Lau; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

6.  Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs.

Authors:  Seth C Kalichman; Tamar Grebler; Christina M Amaral; Megan McNerey; Denise White; Moira O Kalichman; Chauncey Cherry; Lisa Eaton
Journal:  J Gen Intern Med       Date:  2012-10-12       Impact factor: 5.128

Review 7.  Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.

Authors:  Sharon S Lieberman-Blum; Horatio B Fung; Juan C Bandres
Journal:  Clin Ther       Date:  2008-07       Impact factor: 3.393

Review 8.  Preventing HIV antiretroviral resistance through better monitoring of treatment adherence.

Authors:  David R Bangsberg
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

9.  Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients.

Authors:  H-J Epple; T Schneider; H Troeger; D Kunkel; K Allers; V Moos; M Amasheh; C Loddenkemper; M Fromm; M Zeitz; J-D Schulzke
Journal:  Gut       Date:  2008-10-20       Impact factor: 23.059

10.  Maraviroc: in vitro assessment of drug-drug interaction potential.

Authors:  Ruth Hyland; Maurice Dickins; Claire Collins; Hannah Jones; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2008-04-10       Impact factor: 4.335
  10 in total
  5 in total

Review 1.  Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.

Authors:  Guoyan G Xu; Jia Guo; Yuntao Wu
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

3.  CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

Authors:  Yanhui Lu; Edward J Fuchs; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2014-08-12       Impact factor: 3.922

4.  Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.

Authors:  Narasimha M Midde; Namita Sinha; Pradeep B Lukka; Bernd Meibohm; Santosh Kumar
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

Review 5.  Maraviroc: a review of its use in HIV infection and beyond.

Authors:  Shawna M Woollard; Georgette D Kanmogne
Journal:  Drug Des Devel Ther       Date:  2015-10-01       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.